A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder

Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor; an extended-release (ER) formulation allows for once-daily dosing. This phase III study (NCT01034462) evaluated the efficacy, the safety, and the tolerability of 40 to 120 mg/d of levomiln...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sambunaris, Angelo, Bose, Anjana, Gommoll, Carl P., Chen, Changzheng, Greenberg, William M., Sheehan, David V.
Formato: Artigo
Idioma:Inglês
Publicado em: Williams And Wilkins 2014
Assuntos:
Original Contributions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4047313/
https://ncbi.nlm.nih.gov/pubmed/24172209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0000000000000060
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados